Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending

3 1 minute read

Novo Nordisk A/S (NYSE:NVO) has recently been highlighted as one of the 13 Best Extremely Profitable Stocks to Invest in Now, according to a report by Insider Monkey. The pharmaceutical company is making significant efforts to solidify its market position, particularly in the U.S., through increased advertising spending on its GLP-1 medications, Wegovy and Ozempic.

In the first nine months of 2025, Novo Nordisk allocated nearly $500 million towards promoting these medications, which is more than double the spending of rival company Eli Lilly. As supply constraints eased and competition intensified, the company directed $316 million towards Wegovy and $169 million towards Ozempic, marking year-over-year increases of 54% and 44% respectively.

The decision to ramp up advertising comes in response to Eli Lilly’s Zepbound showcasing greater weight-loss efficacy in late 2024 trial data, leading to a surge in U.S. prescription volume. To counter this, Novo plans to promote its upcoming oral version of Wegovy and enhance distribution through cash-pay and direct-to-consumer channels.

Analysts at Citi recently initiated coverage of Novo Nordisk with a ‘Neutral’ rating and a price target of DKK 400, noting that the company’s valuation appears fair despite sustained high demand for obesity treatments. Novo Nordisk, a global pharmaceutical company, specializes in treating rare diseases, diabetes, and obesity.

While Novo Nordisk presents investment potential, there are other opportunities in the market that offer greater upside potential with less downside risk, particularly in the AI sector. Investors seeking undervalued AI stocks may find our free report on the best short-term AI stock insightful.

In conclusion, Novo Nordisk is strategically positioning itself to maintain its market standing and capitalize on the growing demand for its medications. With a focus on innovation and expansion, the company is poised for continued success in the pharmaceutical industry.